Irinotecan Medac (Irinotecan Hydrochloride Trihydrate)

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecan Medac, is a Topoisomerase I inhibitor presented as an injectable formulation for intravenous use. It is employed in the treatment of metastatic colorectal cancer in adult patients, where it targets rapidly dividing tumor cells.

GNH USA supplies Irinotecan Medac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, providing reliable sourcing for oncology treatment programs and ensuring quality and regulatory compliance.

Irinotecan Medac is indicated for cancers of the colorectal system, where it acts as a topoisomerase I inhibitor.

Metastatic colorectal cancer: improves survival when combined with fluoropyrimidine therapy Advanced colorectal adenocarcinoma: reduces tumor progression in later‑line settings Colorectal cancer refractory to first‑line therapy: provides an alternative treatment option

Irinotecan may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Diarrhea: often severe and may require antidiarrheal therapy - Neutropenia: reduced white blood cell count increasing infection risk - Nausea and vomiting: may need antiemetic support - Fatigue: generalized tiredness during treatment - Alopecia: hair loss in some patients - Abdominal cramping: discomfort in the gastrointestinal tract

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count requiring urgent care - Severe colitis or intestinal perforation: life‑threatening gastrointestinal complications - Hepatic toxicity: elevated liver enzymes or bilirubin - Allergic reactions: rash, pruritus, or anaphylaxis - Severe dehydration: secondary to profuse diarrhea - Thromboembolic events: rare clot formation in veins or arteries

Before initiating therapy, clinicians should assess patient‑specific risk factors and monitor for toxicity.

Monitor blood counts: perform regular CBC to detect neutropenia Assess liver function: evaluate hepatic enzymes before and during treatment Maintain hydration: ensure adequate fluid intake to mitigate severe diarrhea Avoid concurrent myelosuppressive agents: reduce risk of compounded bone‑marrow suppression Pregnancy and lactation: contraindicated unless benefits clearly outweigh risks Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake

Irinotecan may interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase irinotecan exposure and toxicity - Concurrent myelosuppressive chemotherapy (e.g., carboplatin): additive bone‑marrow suppression - High‑dose UGT1A1 inhibitors: elevate SN‑38 levels leading to severe neutropenia

Moderate Interactions (Monitor Closely): - Fluoropyrimidines (e.g., 5‑FU): enhanced gastrointestinal toxicity - Radiation therapy to the abdomen: increased risk of severe diarrhea and colitis - Anticholinergic agents: may exacerbate constipation after diarrhea phase